The interaction between Fas and Fas ligand ( FasL ) is involved in the apoptotic death of a number of cells including lymphocytes. Forced expression of FasL in tumors can induce apoptosis of infiltrating Fas -positive T cells; accordingly, tumors can survive in the milieu of systemic immune responses. However, FasL -expressing murine lung carcinoma ( A11 ) and melanoma ( B16 ) cells did not develop subcutaneous tumors and FasL -expressing A11 ( A11 / FasL ) cells produced few spontaneous lung metastatic foci in syngeneic mice. The mice that rejected A11 / FasL cells were resistant to subsequent challenge of parent A11 but not irrelevant B16 cells. Vaccination of mice with UV -treated A11 / FasL, but not UV -treated A11 cells, however, augmented the growth rate of A11 but not B16 tumors, both of which were subsequently inoculated. The number of lung metastatic foci of A11 cells was also increased in the mice that received UV -treated A11 / FasL but not UV -treated A11 cells. Intraperitoneal injection of UV -treated A11 / FasL cells resulted in the production of larger amounts of immunosuppressive TGF -b in peritoneal exudate than that of UV -treated A11 cells. Expression of the CD80 costimulatory molecule in tissues where UV -treated A11 / FasL cells were inoculated was lower than the expression at an untreated A11 / FasL -injected site. Our results indicated that apoptotic FasL -expressing tumor cells could impair host immune responses against the tumors, in contrast to potent antitumor immunity generated by viable FasL -expressing tumors.
F
as is a transmembrane glycoprotein belonging to the tumor necrosis factor receptor family and activates an apoptotic signal pathway upon the ligation with its physiological ligand (Fas ligand, FasL ). 1, 2 The Fas /FasL system has been implicated in clonal deletion of autoreactive lymphocytes and in elimination of activated lymphocytes to down -regulate immune responses. The system thereby plays a crucial role in the maintenance of immune homeostasis. 3 Loss of Fas expression or mutation of the FasL gene in experimental animal models generated lymphoproliferative disorders associated with autoimmune responses. 4, 5 FasL is also involved in one of the effector mechanisms through which cytotoxic T lymphocytes or natural killer cells fulfill their killing function toward target cells. 6 The immune -privileged sites such as testis and the anterior chamber of the eyes, where systemic immunity was poorly induced, expressed FasL locally and induced apoptosis of Fas -positive activated T cells that infiltrated into the tissues. 7, 8 Ectopic expression of FasL in tumors can, therefore, be an escape mechanism of tumors to evade host immune responses. 9 -11 However, forced expression of the FasL gene in tumors induced regression of the tumors, which was postulated to be due to neutrophils -mediated inflammatory reactions. 12 -14 The immunological significance of FasL expression in tumors thereby remains controversial. 15, 16 Local production of cytokines can modulate the effects of expressed FasL; TGF -b inhibited activation of neutrophils and decreased FasL -mediated antitumor activity. 17 In this study, we established murine lung carcinoma ( A11 ) and melanoma ( B16 ) cells expressing FasL and examined whether an antitumor effect or immunological tolerance to tumor cells could be observed in the inoculated mice. We found that the FasL expressed in tumors produced a bipolar effect: induction or suppression of antitumor immunity, depending on the viability status of the tumors.
Materials and methods

Mice and cells
A11 cells, established from Lewis lung carcinoma, 18 and B16 melanoma cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% heat -inactivated fetal calf serum. Syngeneic C57BL /6 mice ( 6-to 8 -weekold females ) were purchased from Japan SLC (Hamamatsu, Japan ).
Establishment of FasL -expressing cells
Cells were transfected with the full -length murine FasL cDNA 1 or vector pMKITneo DNA with a lipofectin reagent ( Life Technologies, Gaithersburg, MD ). G418 ( Life Technologies) resistant clones were selected and examined for their expression of surface FasL with flow cytometry.
B -cell apoptosis
Spleen cells of C57BL /6 mice were incubated with culture supernatants from a myeloma cell line producing fused soluble CD40 ligand ( CD4OL )/ CD8 protein 19 for 2 days. They were added onto adherent tumor cells and cultured for 12 hours. The spleen cells were then stained with fluorescein isothiocyanate -conjugated monoclonal antimouse B220 antibody (PharMingen, San Diego, CA ) and 1 g /mL propidium iodide ( PI) for 20 minutes in the presence of 0.1% ( wt /vol ) sodium azide. The stained cells were analyzed with FACScan ( Becton Dickinson, San Jose, CA ) through the CellQuest software (Becton Dickinson ). Anti -Fas antibody ( Jo-2, 1 ng /mL; PharMingen ) was used as a positive control to induce apoptosis of Fas -positive B cells.
Animal studies
Parent or transfected cells ( 2Â10 5 ) were subcutaneously inoculated into syngeneic mice. Tumor volumes were calculated according to the following formula: 1 /2ÂlengthÂ ( width ) 2 . For spontaneous lung metastasis, parent and transfected cells (2Â10 5 ) were injected subcutaneously into the abdominal flank of mice. The lungs were fixed with 
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Vaccination
Cells were washed with phosphate -buffered saline and were exposed to 200 -J (A11 and A11 /FasL cells) or 600 -J (B16 and B16 /FasL cells ) ultraviolet ( UV ) radiation. They (2Â10 5 ) were then subcutaneously inoculated into syngeneic mice. More than 95% of the cells became apoptotic under the experimental condition. To prepare necrotic cells, cells ( 2Â10 5 ) were frozen and immediately thawed once, and then subcutaneously inoculated into mice. One cycle of the freeze /thaw procedure did not disrupt cells into fragments but kept membrane configuration intact with increased membrane permeability. 21 Mice were immunized with UV-treated or freeze /thaw -treated cells and then were subcutaneously inoculated with parent cells 14 days later.
Measurement of TGF -
UV-treated (200 -J ) or untreated A11 cells ( 1Â10 6 ) were inoculated into the peritoneal cavity of syngeneic mice. Phosphate -buffered saline ( 5 mL ) was injected and aspirated sequentially. The aliquots of the peritoneal exudate were tested for their concentrations of TGF -b with enzymelinked immunosorbent assay ( R&D Systems, Minneapolis, MN ).
Reverse transcription polymerase chain reaction ( RT -PCR )
A11 /FasL cells (1Â10 7 ), either exposed to 200 -J UV or unexposed, were subcutaneously injected into syngeneic mice and, 24 hours later, RNA was extracted from the tissues at the inoculation sites. First -strand cDNA was synthesized with random primers and amplification of an equal amount 
Results
Establishment of FasL -expressing cells
A11 and B16 cells were transfected with FasL cDNA and two clones that expressed the highest level of FasL on cell surface ( A11/ FasL and B16 /FasL, respectively ) were selected. Their ability to kill Fas-positive cells was tested with cocultured spleen B cells that were stimulated with soluble CD40L (Fig 1) . A11 /FasL and B16 /FasL cells, but not their respective parent cells, killed B220 -positive B cells, which came to express Fas molecules upon CD40L stimulation, implying that membrane -bound FasL on A11 or B16 cells was able to induce cell death through the Fas / FasL interaction. Cell proliferation rates in vitro of A11 / FasL and B16 /FasL cells were not different from those of respective parent cells ( data not shown ). Although A11, but 
Decreased tumorigenicity of FasL -expressing tumor cells
We subcutaneously inoculated FasL -expressing cells or their parent cells into syngeneic mice. The mice that received parent or vector DNA -transfected cells developed tumors, whereas those injected with A11 /FasL or B16 / FasL cells did not ( Fig 2, A and B ) . We then inoculated a tumorigenic dose of A11 or B16 cells into the mice that had rejected A11/FasL cells. Half of the mice did not develop A11 tumors and the rest of the mice formed small masses, which did not grow further (tumor volumes developed in naive versus A11 /FasL -rejected mice: P < .01, day 24 ) ( Fig 3A ) . In contrast, all the mice that had rejected A11/ FasL cells developed B16 tumors and the tumor growth was not different from that of B16 tumors in naive mice ( P= .52, day 24 ) ( Fig 3B ) . Tumor-specific protective immunity was, therefore, induced in the mice that rejected A11 /FasL cells. A11 cells produced spontaneous lung metastatic foci when they were subcutaneously inoculated in the flank. However, the number of lung foci was significantly decreased when A11 /FasL cells were inoculated ( Table 1 ) . Expression of FasL in tumors also inhibited spontaneous metastasis of the tumors. (Fig 4A ) . However, immunization with UV-treated A11 /FasL cells significantly enhanced the growth of A11 tumors compared with the growth in untreated mice (P < .01, day 21 ) or in the mice immunized with UV-treated A11 cells (P <.01, day 24) (Fig 4A) . When mice were immunized with freeze /thaw -treated A11/FasL cells, the growth of A11 tumors remained the same as that in untreated mice. The growth was slightly greater than that in the mice immunized with freeze / thawtreated A11 cells ( P= .082, day 24 ) but was suppressed We also examined the vaccination -induced enhanced tumor growth using B16 /FasL cells. Syngeneic mice were immunized with UV-treated B16 or B16 / FasL cells and then subsequently inoculated with B16 cells. Immunization with UV-treated B16 / FasL cells significantly enhanced the growth of B16 tumors compared with that in untreated and immunized mice with UV-treated B16 cells ( P= .020 and P < .01, respectively, day 24 ) ( Fig 4B ) . In contrast, immunization with UV-treated B16 or A11/FasL cells did not affect the tumor growth of B16 cells subsequently inoculated.
Effect of the vaccination on spontaneous lung metastasis was examined by immunization with UV-treated A11 or A11 /FasL cells followed by subcutaneous inoculation of A11 cells (Table 1 ) . Immunization with UV-treated A11 cells did not influence the number of lung foci compared with that of the foci developed in untreated mice. However, the focus number was significantly increased in the mice immunized with UV-treated A11 /FasL cells.
Intraperitoneal concentrations of TGF -by inoculating FasL -expressing cells
We sequentially measured the concentrations of TGF -b in the peritoneal cavity of the mice that received untreated or UV-treated cells (Fig 5 ) . A11 and A11 /FasL cells did not produce detectable amounts of TGF -b in vitro ( < 10 pg /mL ) and the concentration of TGF -b in the peritoneal cavity of naive mice was 100± 25 (pg /mL ± SE ). When untreated or UV-treated A11 cells were inoculated, the amount of TGF -b became maximal at 9 hours after the inoculation and returned to an uninjected level. The amount at each time was not different between untreated A11 and UVtreated A11-injected mice. Inoculation of A11 /FasL cells, untreated or UV-treated, increased the amount of TGF -b after the inoculation (untreated cells-injected, 3 vs 24 hours, P=.015; treated cells -injected, 3 vs 24 hours, P < .01 ). The amount of TGF -b at 24 hours in the mice injected with UV-treated A11 /FasL cells was significantly larger than that in untreated A11/FasL -or A11-injected mice (P < .01). In contrast, the concentrations of TNF -a were not different between the mice injected with UVtreated A11 cells and those with UV-treated A11 /FasL cells ( data not shown ).
Expression of CD80 at tumor injection sites
We compared the expression of the CD4, CD8a, CD40, and CD80 genes in tissues where UV-treated or untreated A11 / FasL cells were injected (Fig 6 ) . Expression of the CD4, CD8a, and CD40 genes was higher at the injection site of UV-treated A11/ FasL cells than that at the untreated A11 / FasL cells -injected site. In contrast, expression of CD80 costimulator molecule was lower at the injection site of UV-treated A11 /FasL cells. These data suggest that CD40 + antigen-presenting cells, CD4 + , and CD8 + T cells migrated into the injection site of UV-treated A11/ FasL cells better than that of untreated A11 /FasL cells; however, dendritic cells (DCs ) at the injection site of UV-treated A11/FasL cells were less activated compared with those at A11/FasL cells -injected site.
Discussion
In this study, we showed that immunocompetent mice produced significant antitumor effects on FasL -expressing 
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Apoptotic FasL -expressing tumors suppresses immunity Y Tada et al murine carcinoma cells, and the mice that had rejected FasLexpressing tumors generated tumor-specific protective immunity. Although the present study suggested that cytotoxic T cells specific for FasL -expressing tumors were generated, a possible involvement of other cell populations in the FasLmediated antitumor responses cannot be excluded. Previous studies reported that neutrophils -mediated inflammatory reactions were primarily responsible for FasL -mediated antitumor effects 12, 13 and our separate experiments showed that A11/ FasL cells were also rejected in T cell -defective nude mice and that intraperitoneal inoculation of A11 /FasL cells induced neutrophil -dominant peritoneal exudation. However, we observed that mice inoculated with a mixed population of A11 /FasL and B16 cells developed B16 but not A11/ FasL tumors, suggesting that T cells, which recognize the specificity of tumors, could be actively involved in FasL -mediated antitumor responses ( manuscript in preparation ). Extravasation of neutrophils and subsequent release of proinflammatory cytokines from neutrophils can be an initial step for antitumor responses, but we presume that prompt migration of DCs into the tumors and subsequent cognate interaction between antigen -loaded DCs and naive T cells facilitate the development of T cell -dependent systemic immunity.
Although the FasL -expressing tumors induced systemic immunity, vaccination effects were not achieved with the UV-treated FasL -expressing tumors. Immunization of mice with A11 cells, treated either with UV or freeze /thaw procedure, retarded subsequent growth of A11 tumors, suggesting that A11 cells were immunogenic to stimulate systemic immunity. The level of the antitumor activity triggered by the immunization was the same irrespective of the treatment procedure. However, immunization with UVtreated but not freeze /thaw -treated A11 /FasL cells enhanced the growth of A11 but not B16 tumors. The enhanced tumor growth was also achieved by the immunization with UV-treated B16 /FasL cells. Suppression of systemic immunity was confirmed in the experimental lung metastasis system. Administration of apoptotic FasLexpressing tumor cells, therefore, induced a tumor-specific tolerant state. Melcher et al 22 suggested that tumor cell death by nonapoptotic mechanisms was associated with high immunogenicity, whereas apoptotic cells were considerably less immunogenic. Upon apoptotic cell death, macrophages phagocytose the apoptotic cells and produce immunoregulatory factors such as IL -10 and TGF -b that skew immunity to suppressive and anti -inflammatory responses; the production of proinflammatory cytokines was suppressed. 23, 24 Our study, in fact, demonstrated the increase of TGF -b but not TNF -a in the mice that received apoptotic FasLexpressing cells. Although macrophages can play an important role in noninflammatory and nonimmunogenic clearance of cells undergoing apoptosis, 25 we have not histologically detected the migration of macrophages at the inoculation sites.
DCs can also contribute to the silencing of immune responses. Immature DCs phagocytose apoptotic cells; however, they do not efficiently cross -present antigens or activate cytotoxic T cells unless they receive maturation stimuli such as TNF -a. 21 Uptake of apoptotic cells can thereby allow DCs to induce peripheral tolerance to putative tumor antigen(s) in the presence of immunosuppressive cytokines. 26 On the contrary, exposure of DCs to necrotic tumor cells provides requisite maturation signals, which results in the up -regulation of costimulatory molecules and in the augmented induction of antigen -specific CD4 + and CD8 + T cells. 21 At the site where UV-treated A11/FasL cells were inoculated, expression of the CD80 costimulatory molecule was relatively low compared with that of CD40. As CD40 and CD80 are up-regulated upon the maturation of DCs, 21 the increased expression of CD40 observed at the inoculation site of UV-treated cells could be due to increased numbers of DCs and /or B cells. Relatively lower expression of the CD80 gene compared with expression of the CD4, CD8a, and CD40 genes suggests that cognate interaction of DCs and T cells was impaired, although T and antigenpresenting cells were migrated into the inoculation site. Inoculation of UV-treated FasL -expressing tumors thereby suppressed the maturation of DCs. Our separate experiments showed that bone marrow -derived DCs could form cluster in vitro with Fas -expressing, but not with parent tumor, cells ( manuscript in preparation). We thereby presume that immature DCs interact with FasL -expressing tumors in vivo but could not be mature partly due to TGF -b and other immunosuppressive cytokines secreted from macrophages; consequently, T cell -mediated antitumor immunity is suppressed. TGF -b, in fact, prevents the maturation of DCs, 27 and Chen et al 17 demonstrated that secretion of TGF -b from FasL -expressing tumors allowed the tumor growth; otherwise, FasL-expressing tumors were rejected.
In conclusion, forced expression of the FasL gene in tumors generated bivalent immune responses; live FasLexpressing tumors induced systemic antitumor responses, whereas apoptotic tumors suppressed antitumor immunity. Expression of FasL in live tumors is a possible therapeutic strategy for cancer but apoptotic cells included in the preparation can lessen the therapeutic effects. Depletion of immunosuppressive cytokines and provision of maturation signals to DCs can be crucial to shift a possible FasL -mediated tolerance toward systemic antitumor responses.
